STOCK TITAN

Rallybio (RLYB) SEC Filings, Oct-Nov 2026

RLYB NASDAQ

Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.

The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.

Rhea-AI Summary

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber exercised options on October 29, 2026, acquiring 7,875 common shares at $14.88 per share and 13,589 common shares at $6.08 per share. The options’ vesting was accelerated in full, and they became fully vested and exercisable on October 26, 2026. No Rule 10b5-1 plan is reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
insider
-
Rhea-AI Summary

Ronald Hunt, a director of Rallybio Corp, exercised options covering 14,820 common shares on October 29, 2026, and acquired the underlying shares. The options had exercise prices of $2.38, $7.60 and $15.28 per share. The option covering 9,196 shares was issued in lieu of $51,500 in retainer fees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
insider
-
Rhea-AI Summary

Rallybio Corp (RLYB) director Christine A. Nash exercised 3,562 options on October 28, 2026, at an exercise price of $2.38 per share, acquiring 3,562 common shares. Her reported position after the transaction was 3,562 common shares, and the option position following the transaction was 0. The option was granted under the company's 2021 Equity Incentive Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
insider
Rhea-AI Summary

Rallybio Corp Chief Executive Officer Stephen Uden exercised options on October 27, 2026, to acquire 33,244 common shares at an exercise price of $6.08 per share. His directly held common-stock position after the exercise was 148,864 shares. The reported option balance after the transaction was 0 shares, and the option's expiration date was February 14, 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
insider
-
Rhea-AI Summary

Rallybio Corp (RLYB) Chief Financial Officer Jonathan I. Lieber reported acquiring 2,500 shares of common stock on October 26, 2026, followed by a sale of 599 shares on October 27, 2026, at $16.04 per share. The sale occurred upon partial vesting of a performance stock award solely to satisfy tax withholding obligations incurred upon vesting. No Rule 10b5-1 plan was reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
insider
-
Rhea-AI Summary

Rallybio Corp director Wendy Chung exercised options on October 26, 2026, to acquire 2,062 common shares at an exercise price of $15.28 per share. Her direct common-stock holdings after the transaction were 5,624 shares. The option was granted under Rallybio's 2021 Equity Incentive Plan and is listed with an expiration date of May 15, 2034.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.63%
Tags
insider
Rhea-AI Summary

Rallybio Corp. reported a third-quarter net loss of $2.725 million, compared with net income of $16.016 million in 2025; collaboration and license revenue was $0, versus $212,000. Nine-month net income was $32.662 million and included a $50.0 million termination fee received after Candid ended the earlier merger agreement. Cash and cash equivalents were $90.693 million at September 30, 2026.

Rallybio’s proposed merger with Avenzo would make Avenzo a wholly owned subsidiary and change Rallybio’s name to Avenzo Therapeutics. Avenzo’s $215.0 million concurrent financing is conditioned on satisfaction or waiver of merger-closing conditions and certain other conditions. Under pro forma assumptions, including $215.0 million in gross financing proceeds, Avenzo’s pre-merger holders are expected to own approximately 56.6% of the combined company, financing investors approximately 40.6%, and Rallybio’s pre-merger holders approximately 2.8%; ownership may be adjusted, including based on final Rallybio Net Cash. The merger was anticipated to close before the end of 2026. Rallybio will declare distributions of Rallybio Net Cash to eligible holders before closing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
quarterly report
-
Rhea-AI Summary

Rallybio Corp declared a special cash distribution in connection with its proposed merger with Avenzo Therapeutics, estimated at an aggregate of $82.7 million, or $13.56 per share. The estimate is based on net cash calculated under the merger agreement before closing, to the extent it exceeds $0, and the final amount may be higher or lower. Payment is conditioned on receipt of the required company stockholder vote at the November 4, 2026 annual meeting.

The distribution is payable to stockholders and pre-funded warrant holders of record on November 5, 2026, a date subject to change based on the meeting date; payment is scheduled for November 13, 2026. Common-stock trades during the expected November 4–6, 2026 due bill period transfer distribution entitlement to buyers, even if settlement occurs after the period. The merger closing is expected on or about November 6, 2026, subject to stockholder approval and satisfaction or waiver of merger conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
merger
-
Rhea-AI Summary

Rallybio Corp. (RLYB) declared a special cash distribution estimated at $82.7 million, or $13.56 per share, for stockholders and pre-funded warrant holders. The estimate is based on the company’s good-faith calculation of net cash above $0 under the merger agreement; the actual distribution may be higher or lower. Payment is conditioned on receipt of the Required Company Stockholder Vote at the annual meeting scheduled for November 4, 2026.

The record date is November 5, 2026, subject to change based on the stockholder meeting date. The company plans to deposit the actual distribution with its transfer agent that day, with payment scheduled for November 13, 2026. The merger with Avenzo Therapeutics, Inc. is expected to close on or about November 6, subject to stockholder approval and satisfaction or waiver of the merger agreement’s conditions. The expected November 4–6 due-bill period means sellers deliver the distribution to buyers of shares traded during that period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
current report
Rhea-AI Summary

Rallybio Corp (RLYB) director Paula Soteropoulos exercised options to acquire 3,562 common shares on October 16, 2026, at an exercise price of $2.38 per share. She directly held 6,544 common shares after the exercise. The option was granted under Rallybio's 2021 Equity Incentive Plan and expires May 13, 2035.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
insider

FAQ

How many Rallybio (RLYB) SEC filings are available on StockTitan?

StockTitan tracks 83 SEC filings for Rallybio (RLYB), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Rallybio (RLYB)?

The most recent SEC filing for Rallybio (RLYB) was filed on November 12, 2026.